Nautilus Biotechnology
Nautilus Biotechnology develops the Voyager platform, which uses Iterative Mapping technology for accurate single-molecule quantification of proteins and proteoforms. Its products are designed for researchers in drug development, biomarker discovery, and exploratory biology to provide comprehensive views of the proteome and support deep biological insights. The organization aims to revolutionize biomedicine by unlocking the complexity of the proteome to positively impact global health.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2016
- Employees
- 148
- Stage
- Public
- Members see funding amounts. .
- Founders
- Sujal Patel, Parag Mallick, PhD
Is this your organization? Claim it
Nautilus to Receive Up to $6M from ARPA-H SEEDS Consortium to Measure Proteoforms Driving Alzheimer’s and Ewing Sarcoma
Nautilus joins the ARPA-H-funded SEEDS consortium and expects up to $6 million to deploy its Voyager platform to measure proteoforms linked to Alzheimer’s disease and Ewing sarcoma, supporting a $51.7 million, four-year effort to predict misfolding of intrinsically disordered proteins and enable earlier detection and intervention. The consortium is co-led by the Buck Institute and Georgetown University and will combine protein science, AI, and computational approaches to study disease-causing protein behavior.
People
See all 4-
Sujal Patel Executive Officer, Director, Founder & CEO
-
Parag Mallick Founder & Chief Scientist
-
Anna Mowry Executive, Chief Financial Officer